Panacea Biotec reports audited standalone and consolidated results for Q4 FY2026 with an unmodified auditor’s opinion. Dividend on equity and preference shares is skipped due to losses. The board also appoints Rajinder Singh Manku as an additional non-exec independent director for five years from July 1, 2026, subject to shareholder approval.